Assignee
NANOPHARMACEUTICALS LLC
US·14 granted patents·1 pending application·79 citations·filing 2014–2021
Top patents by PatentIndex Score
15 records- 0196US10961204B1Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumorsNANOPHARMACEUTICALS LLC·Filed 2020·Granted Mar 30, 2021·4 cites·18 claims
- 0295US9579300B2Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereofNANOPHARMACEUTICALS LLC·Filed 2014·Granted Feb 28, 2017·13 cites·19 claims
- 0395US9498536B2Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disordersNANOPHARMACEUTICALS LLC·Filed 2014·Granted Nov 22, 2016·16 cites·23 claims
- 0494US10130686B2Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disordersNANOPHARMACEUTICALS LLC·Filed 2016·Granted Nov 20, 2018·7 cites·20 claims
- 0594US9750709B2Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereofNANOPHARMACEUTICALS LLC·Filed 2014·Granted Sep 5, 2017·11 cites·13 claims
- 0690US10328043B1Composition and method for dual targeting in treatment of neuroendocrine tumorsNANOPHARMACEUTICALS LLC·Filed 2018·Granted Jun 25, 2019·11 cites·21 claims
- 0790US9839614B2Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereofNANOPHARMACEUTICALS LLC·Filed 2015·Granted Dec 12, 2017·9 cites·13 claims
- 0887US10201616B2Non-cleavable polymer conjugated with αVβ3 integrin thyroid antagonistsNANOPHARMACEUTICALS LLC·Filed 2017·Granted Feb 12, 2019·6 cites·23 claims
- 0985US11077082B2Composition and method for dual targeting in treatment of neuroendocrine tumorsNANOPHARMACEUTICALS LLC·Filed 2019·Granted Aug 3, 2021·2 cites·22 claims
- 1068US11186551B2Composition of scalable thyrointegrin antagonists with improved retention in tumorsNANOPHARMACEUTICALS LLC·Filed 2021·Granted Nov 30, 2021·0 cites·12 claims
- 1167US10695436B2Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonistsNANOPHARMACEUTICALS LLC·Filed 2018·Granted Jun 30, 2020·0 cites·19 claims
- 1259US11723888B2Polymer conjugated thyrointegrin antagonistsNANOPHARMACEUTICALS LLC·Filed 2021·Granted Aug 15, 2023·0 cites·13 claims
- 1354US11351137B2Composition and method for dual targeting in treatment of neuroendocrine tumorsNANOPHARMACEUTICALS LLC·Filed 2021·Granted Jun 7, 2022·0 cites·14 claims
- 1454US10060934B2Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereofNANOPHARMACEUTICALS LLC·Filed 2014·Granted Aug 28, 2018·0 cites·9 claims
- 1549US2016178615A1Rgd-binding compounds and methods of useNANOPHARMACEUTICALS LLC·Filed 2016·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →